Voranigo is a targeted therapeutic drug for IDH1/2-mutant low-grade gliomas (grade 2 astrocytomas or oligodendrogliomas). As a new type of isocitrate dehydrogenase inhibitor, its efficacy has been verified in clinical trials, but patients need to fully understand its potential side effects and medication precautions.
What Are the Side Effects of Voranigo?
Common Side Effects
Systemic reactions: Fatigue (33%-37%), COVID-19 infection (28%-33%).
Neurological symptoms: Headache (28%), seizures (16%).
Musculoskeletal discomfort: Muscle or joint pain (24%-26%).
Gastrointestinal reactions: Diarrhea (21%-25%), nausea (20%), constipation (13%).
Laboratory Abnormalities
Elevation of alanine aminotransferase (ALT): 59% of patients, among which 9%-10% are grade 3-4.
Elevation of aspartate aminotransferase (AST): 46% of patients, among which 4.8% are grade 3-4.
Elevation of gamma-glutamyl transferase (GGT): 38% of patients, among which 3% are grade 3-4.
Neutropenia: 14% of patients, among which 2.4% are grade 3-4.
Serious Side Effects of Voranigo to Be Alert For
Hepatotoxicity
Voranigo may cause a significant increase in liver enzymes, and even lead to liver failure or autoimmune hepatitis.
Clinical manifestations: Jaundice, tea-colored urine, right upper abdominal pain, extreme fatigue.
Monitoring requirements: Liver function (ALT/AST/GGT/bilirubin/alkaline phosphatase) should be tested before medication and every 2 weeks in the early stage of treatment.
After 2 years of treatment, the monitoring frequency should be changed to once a month; if abnormalities occur, the monitoring frequency needs to be increased.
Management measures:
Grade 1 elevation (ALT/AST > ULN - 3×ULN): Continue medication and monitor weekly until recovery.
Grade 2 elevation (> 3 - 5×ULN): For the first occurrence, suspend medication; patients who recover within 28 days can continue with the original dose; if it recurs, dose reduction is required.
Grade 3 elevation (> 5 - 20×ULN) or accompanied by bilirubin > 2×ULN: Discontinue medication permanently.
Embryo-Fetal Toxicity
Animal studies have shown that Voranigo can cause fetal malformations (such as abnormal development of the kidneys, testes, and heart).
Contraceptive requirements:
Female patients: Non-hormonal contraceptive measures should be used during medication and for 3 months after discontinuing the drug (because the drug may reduce the effectiveness of hormonal contraceptives).
Male patients: Ensure that their partners use effective contraception during medication and for 3 months after discontinuing the drug.
Other Serious Reactions
Seizures: 3.6% of patients need to discontinue medication permanently, and 4.2% experience grade 3-4 seizures.
Infection risk: The infection rate of COVID-19 is 28%-33%, which requires close monitoring.
Precautions for Voranigo Administration
Drug Interactions
Strong/moderate CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): May increase the blood concentration of Voranigo.
Moderate CYP1A2 inducers (e.g., phenytoin, rifampicin) and tobacco: May reduce the efficacy of the drug.
Drugs that are CYP3A substrates (e.g., certain anticoagulants, immunosuppressants): Voranigo may reduce their efficacy.
Administration in Special Populations
Mild to moderate hepatic impairment (Child-Pugh A/B) or CrCl > 40 mL/min: No dose adjustment is required.
Severe hepatic impairment (Child-Pugh C) or CrCl ≤ 40 mL/min: Enhanced monitoring is required.
